Empire Financial Management Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Empire Financial Management Company’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$780K	–	212
2025 Q4	$780K	Buy	+100,000	New	+$723K	0.17%	125
2025 Q1	–	Sell	-35,000	Closed	-$263K	–	200
2024 Q4	$263K	Sell	35,000 -24,000	-41%	-$182K	0.08%	176
2024 Q3	$448K	Hold	59,000	–	–	0.14%	154
2024 Q2	$365K	Sell	59,000 -20,000	-25%	-$110K	0.12%	158
2024 Q1	$401K	Buy	79,000 +5,500	+7%	+$30.9K	0.13%	158
2023 Q4	$440K	Buy	73,500 +26,000	+55%	+$151K	0.17%	141
2023 Q3	$336K	Buy	47,500 +5,000	+12%	+$35.9K	0.15%	148
2023 Q2	$299K	Buy	42,500 +12,500	+42%	+$100K	0.12%	165
2023 Q1	$250K	Buy	+30,000	New	+$289K	0.1%	178

Other funds holding BCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return